tazarotene has been researched along with Dermatitis, Contact in 3 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Dermatitis, Contact: A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 6.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| " Safety and treatment emergent adverse events (TEAEs) were evaluated throughout." | 2.90 | Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials ( Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lebwohl, MG | 1 |
| Sugarman, JL | 1 |
| Stein Gold, L | 2 |
| Lin, T | 2 |
| Israel, R | 1 |
| Elewski, B | 1 |
| Draelos, Z | 1 |
| Jacobson, A | 1 |
| Berg, JE | 1 |
| Bowman, JP | 1 |
| Saenz, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers[NCT01114841] | Phase 1 | 254 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for tazarotene and Dermatitis, Contact
| Article | Year |
|---|---|
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Topics: Adult; Clobetasol; Dermatitis, Contact; Dermatologic Agents; Double-Blind Method; Drug Combinations; | 2019 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Topics: Adult; Aged; Clobetasol; Dermatitis, Contact; Double-Blind Method; Drug Combinations; Female; Humans | 2020 |
Cumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studies.
Topics: Administration, Cutaneous; Adult; Dermatitis, Contact; Dermatologic Agents; Humans; Male; Middle Age | 2012 |